| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 36 | 2014 | 1341 | 1.870 |
Why?
|
| Uterine Neoplasms | 24 | 2011 | 545 | 1.120 |
Why?
|
| Hysterectomy | 20 | 2013 | 611 | 0.850 |
Why?
|
| Uterine Cervical Neoplasms | 31 | 2008 | 1833 | 0.850 |
Why?
|
| Vulvar Neoplasms | 16 | 2004 | 236 | 0.820 |
Why?
|
| Interdisciplinary Communication | 2 | 2010 | 280 | 0.620 |
Why?
|
| Gynecology | 6 | 2009 | 217 | 0.530 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2009 | 323 | 0.490 |
Why?
|
| Ovarian Neoplasms | 30 | 2005 | 4638 | 0.480 |
Why?
|
| Cystadenocarcinoma, Papillary | 9 | 2005 | 82 | 0.450 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2013 | 852 | 0.440 |
Why?
|
| Hazardous Waste | 2 | 2002 | 3 | 0.440 |
Why?
|
| Paclitaxel | 9 | 2013 | 1996 | 0.440 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2011 | 107 | 0.430 |
Why?
|
| Hormone Antagonists | 2 | 2009 | 101 | 0.420 |
Why?
|
| Environmental Monitoring | 2 | 2002 | 105 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 40 | 2011 | 10035 | 0.410 |
Why?
|
| Mifepristone | 2 | 2009 | 147 | 0.410 |
Why?
|
| Mandatory Reporting | 1 | 2011 | 24 | 0.400 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2013 | 486 | 0.390 |
Why?
|
| Neoplasm Staging | 50 | 2013 | 13658 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 25 | 2003 | 5437 | 0.370 |
Why?
|
| Adenocarcinoma | 24 | 2009 | 7789 | 0.360 |
Why?
|
| Public Health Practice | 1 | 2009 | 22 | 0.360 |
Why?
|
| Disclosure | 1 | 2011 | 181 | 0.360 |
Why?
|
| Female | 159 | 2021 | 141928 | 0.350 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 14 | 0.350 |
Why?
|
| Community-Institutional Relations | 1 | 2009 | 42 | 0.350 |
Why?
|
| Medical Oncology | 5 | 2013 | 1423 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2011 | 15862 | 0.330 |
Why?
|
| Middle Aged | 111 | 2021 | 86204 | 0.320 |
Why?
|
| Lymph Node Excision | 13 | 2004 | 1959 | 0.310 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 348 | 0.300 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 313 | 0.300 |
Why?
|
| Brachytherapy | 3 | 2013 | 977 | 0.300 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 244 | 0.300 |
Why?
|
| Adult | 103 | 2021 | 77950 | 0.290 |
Why?
|
| Humans | 169 | 2021 | 261506 | 0.290 |
Why?
|
| Environmental Pollutants | 2 | 2018 | 83 | 0.280 |
Why?
|
| Genital Neoplasms, Female | 7 | 2009 | 735 | 0.280 |
Why?
|
| Pelvic Exenteration | 6 | 1996 | 108 | 0.280 |
Why?
|
| Thiophenes | 2 | 2003 | 148 | 0.270 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2003 | 145 | 0.260 |
Why?
|
| Aged | 85 | 2014 | 70117 | 0.250 |
Why?
|
| Intestinal Fistula | 2 | 1995 | 44 | 0.250 |
Why?
|
| Quality Improvement | 1 | 2011 | 851 | 0.240 |
Why?
|
| Cisplatin | 20 | 2006 | 2432 | 0.240 |
Why?
|
| Follow-Up Studies | 22 | 2021 | 14889 | 0.230 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 860 | 0.230 |
Why?
|
| Vaginal Neoplasms | 4 | 2003 | 152 | 0.220 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 4 | 2005 | 35 | 0.220 |
Why?
|
| Urban Health | 1 | 2002 | 75 | 0.220 |
Why?
|
| Choriocarcinoma | 1 | 2002 | 47 | 0.210 |
Why?
|
| Societies, Medical | 1 | 2009 | 1335 | 0.210 |
Why?
|
| Industry | 1 | 2002 | 53 | 0.210 |
Why?
|
| Neoplasms | 5 | 2011 | 15193 | 0.210 |
Why?
|
| Colostomy | 2 | 1996 | 70 | 0.210 |
Why?
|
| Carboplatin | 7 | 2011 | 823 | 0.210 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2002 | 262 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2013 | 3890 | 0.200 |
Why?
|
| Survival Analysis | 23 | 2013 | 9180 | 0.200 |
Why?
|
| Trophoblasts | 1 | 2002 | 138 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 177 | 0.200 |
Why?
|
| Dyspepsia | 1 | 2002 | 103 | 0.200 |
Why?
|
| Piperidines | 2 | 2003 | 1035 | 0.190 |
Why?
|
| Endometrial Hyperplasia | 2 | 2005 | 112 | 0.190 |
Why?
|
| Surgical Flaps | 4 | 1996 | 927 | 0.190 |
Why?
|
| Radiotherapy | 11 | 2003 | 1824 | 0.190 |
Why?
|
| Viruses | 1 | 2021 | 159 | 0.180 |
Why?
|
| Aged, 80 and over | 41 | 2014 | 29902 | 0.180 |
Why?
|
| Public Health | 1 | 2002 | 299 | 0.170 |
Why?
|
| Environmental Exposure | 2 | 2018 | 288 | 0.160 |
Why?
|
| Carcinoma | 9 | 2000 | 2578 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 840 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 521 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2021 | 398 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 3976 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Lymphatic Metastasis | 15 | 2014 | 4844 | 0.150 |
Why?
|
| Vulva | 3 | 1994 | 37 | 0.150 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2004 | 37 | 0.150 |
Why?
|
| Arsenic | 1 | 2018 | 49 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 437 | 0.150 |
Why?
|
| Bacteria | 1 | 2021 | 611 | 0.150 |
Why?
|
| Ureter | 2 | 1996 | 209 | 0.150 |
Why?
|
| Survival Rate | 23 | 2011 | 12221 | 0.140 |
Why?
|
| Toxicology | 1 | 2016 | 14 | 0.140 |
Why?
|
| Urinary Diversion | 1 | 1996 | 69 | 0.140 |
Why?
|
| Treatment Outcome | 20 | 2013 | 32848 | 0.140 |
Why?
|
| Risk Factors | 13 | 2014 | 17523 | 0.140 |
Why?
|
| Combined Modality Therapy | 18 | 2008 | 8865 | 0.130 |
Why?
|
| Lymph Nodes | 9 | 2006 | 2967 | 0.130 |
Why?
|
| Colonic Diseases | 1 | 1996 | 71 | 0.130 |
Why?
|
| Fistula | 1 | 1996 | 76 | 0.130 |
Why?
|
| Vaginal Diseases | 1 | 1995 | 26 | 0.130 |
Why?
|
| Risk Assessment | 6 | 2018 | 6869 | 0.130 |
Why?
|
| Perineum | 1 | 1995 | 107 | 0.130 |
Why?
|
| Urinary Bladder Fistula | 1 | 1994 | 13 | 0.120 |
Why?
|
| Cholecystitis | 1 | 1994 | 52 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 1996 | 223 | 0.120 |
Why?
|
| Prospective Studies | 17 | 2013 | 12873 | 0.120 |
Why?
|
| Etoposide | 6 | 2005 | 870 | 0.120 |
Why?
|
| Infusions, Intravenous | 5 | 2013 | 1382 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 5 | 2005 | 821 | 0.120 |
Why?
|
| Prognosis | 21 | 2021 | 21713 | 0.120 |
Why?
|
| Idarubicin | 1 | 1995 | 446 | 0.110 |
Why?
|
| Salpingectomy | 1 | 2013 | 43 | 0.110 |
Why?
|
| Taxoids | 3 | 2005 | 967 | 0.110 |
Why?
|
| Baltimore | 2 | 2002 | 28 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2006 | 1415 | 0.110 |
Why?
|
| Ovariectomy | 2 | 2013 | 330 | 0.110 |
Why?
|
| Colon | 1 | 1996 | 670 | 0.110 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2013 | 133 | 0.110 |
Why?
|
| Retrospective Studies | 30 | 2021 | 37905 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2013 | 3472 | 0.110 |
Why?
|
| Salvage Therapy | 3 | 1995 | 2054 | 0.100 |
Why?
|
| Gallbladder Neoplasms | 1 | 1994 | 245 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1994 | 328 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 1995 | 450 | 0.100 |
Why?
|
| United States | 6 | 2021 | 15433 | 0.100 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 306 | 0.100 |
Why?
|
| Rosaniline Dyes | 3 | 2004 | 108 | 0.100 |
Why?
|
| Uterus | 1 | 1995 | 678 | 0.090 |
Why?
|
| Platinum Compounds | 2 | 2004 | 131 | 0.090 |
Why?
|
| Biopsy | 8 | 2003 | 3443 | 0.090 |
Why?
|
| Health Care Reform | 1 | 2010 | 68 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 78 | 0.090 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 565 | 0.090 |
Why?
|
| Connecticut | 1 | 2009 | 33 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2006 | 2231 | 0.090 |
Why?
|
| ras Proteins | 1 | 2014 | 770 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 146 | 0.090 |
Why?
|
| Environmental Health | 2 | 2016 | 21 | 0.090 |
Why?
|
| Recurrence | 5 | 2010 | 4758 | 0.090 |
Why?
|
| Community Networks | 1 | 2009 | 45 | 0.090 |
Why?
|
| Receptors, Progesterone | 3 | 2009 | 1392 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 1992 | 467 | 0.090 |
Why?
|
| Laryngeal Neoplasms | 1 | 2013 | 518 | 0.090 |
Why?
|
| Cause of Death | 2 | 2002 | 752 | 0.090 |
Why?
|
| Sclerosing Solutions | 1 | 1989 | 27 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2009 | 76 | 0.080 |
Why?
|
| Sirolimus | 2 | 2010 | 814 | 0.080 |
Why?
|
| Tetracycline | 1 | 1989 | 90 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 164 | 0.080 |
Why?
|
| ROC Curve | 2 | 2021 | 1183 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 585 | 0.080 |
Why?
|
| Vinblastine | 3 | 1998 | 453 | 0.080 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 713 | 0.080 |
Why?
|
| Analgesia, Epidural | 1 | 1989 | 102 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 1988 | 135 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 342 | 0.080 |
Why?
|
| Life Tables | 6 | 1994 | 120 | 0.080 |
Why?
|
| Adolescent | 14 | 2013 | 31252 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2008 | 1823 | 0.080 |
Why?
|
| Surgical Staplers | 1 | 1987 | 5 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 1989 | 201 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 1995 | 1202 | 0.070 |
Why?
|
| Students | 1 | 2009 | 324 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2011 | 621 | 0.070 |
Why?
|
| Radiation Injuries | 5 | 2004 | 1411 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2010 | 1546 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2010 | 785 | 0.070 |
Why?
|
| Lymphography | 3 | 2002 | 51 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 2488 | 0.070 |
Why?
|
| Piperazines | 2 | 2005 | 2101 | 0.070 |
Why?
|
| Antineoplastic Agents | 9 | 2010 | 14289 | 0.070 |
Why?
|
| Research Design | 1 | 2013 | 1544 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2005 | 551 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 543 | 0.070 |
Why?
|
| Progestins | 1 | 2005 | 87 | 0.070 |
Why?
|
| Losartan | 1 | 2005 | 46 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2008 | 986 | 0.060 |
Why?
|
| Mesna | 3 | 2003 | 65 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 68 | 0.060 |
Why?
|
| Premenopause | 1 | 2005 | 131 | 0.060 |
Why?
|
| Age Distribution | 2 | 2004 | 698 | 0.060 |
Why?
|
| Carcinoma, Adenosquamous | 2 | 2002 | 103 | 0.060 |
Why?
|
| Incidence | 6 | 2005 | 5673 | 0.060 |
Why?
|
| Doxorubicin | 6 | 1994 | 3005 | 0.060 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2004 | 19 | 0.060 |
Why?
|
| Cyclophosphamide | 8 | 2001 | 3001 | 0.060 |
Why?
|
| Postmenopause | 2 | 2004 | 378 | 0.060 |
Why?
|
| Disease-Free Survival | 7 | 2006 | 10001 | 0.060 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 107 | 0.060 |
Why?
|
| Ifosfamide | 3 | 2003 | 344 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 874 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 153 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 229 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2005 | 2588 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 8 | 1998 | 3981 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6207 | 0.060 |
Why?
|
| Radiation Oncology | 1 | 2008 | 529 | 0.060 |
Why?
|
| Waste Management | 1 | 2002 | 3 | 0.060 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 183 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 1879 | 0.050 |
Why?
|
| Population Surveillance | 2 | 1997 | 627 | 0.050 |
Why?
|
| Epidemiological Monitoring | 1 | 2002 | 73 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2005 | 3518 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2002 | 108 | 0.050 |
Why?
|
| Pelvic Neoplasms | 3 | 1996 | 189 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 4744 | 0.050 |
Why?
|
| Cities | 1 | 2002 | 49 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2001 | 266 | 0.050 |
Why?
|
| Environmental Pollution | 1 | 2002 | 19 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2013 | 16273 | 0.050 |
Why?
|
| Information Systems | 1 | 2002 | 54 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 395 | 0.050 |
Why?
|
| Geography | 1 | 2002 | 140 | 0.050 |
Why?
|
| Sexual Behavior | 2 | 1996 | 310 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 105 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2002 | 83 | 0.050 |
Why?
|
| Colon, Sigmoid | 1 | 2001 | 42 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2002 | 111 | 0.050 |
Why?
|
| Postoperative Care | 3 | 1994 | 739 | 0.050 |
Why?
|
| Granulosa Cell Tumor | 2 | 1999 | 77 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2004 | 731 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 243 | 0.050 |
Why?
|
| Postoperative Complications | 8 | 2004 | 5542 | 0.050 |
Why?
|
| Child | 5 | 2013 | 29154 | 0.050 |
Why?
|
| Medical Records | 1 | 2002 | 415 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2002 | 94 | 0.050 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 205 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6100 | 0.050 |
Why?
|
| Pelvis | 3 | 2001 | 362 | 0.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2005 | 469 | 0.050 |
Why?
|
| Urban Population | 1 | 2002 | 269 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2001 | 102 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 665 | 0.050 |
Why?
|
| Social Class | 1 | 2002 | 310 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 604 | 0.050 |
Why?
|
| Pericardium | 1 | 2001 | 157 | 0.050 |
Why?
|
| Immunotherapy, Active | 1 | 2000 | 46 | 0.050 |
Why?
|
| Pain | 1 | 1989 | 1658 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2000 | 749 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 309 | 0.050 |
Why?
|
| Apoptosis | 2 | 2007 | 7591 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2004 | 6550 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 2 | 2005 | 1350 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 11538 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 1998 | 573 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 2001 | 214 | 0.040 |
Why?
|
| Immunohistochemistry | 6 | 2007 | 7548 | 0.040 |
Why?
|
| Quality of Life | 1 | 2013 | 4532 | 0.040 |
Why?
|
| Food Contamination | 1 | 2018 | 22 | 0.040 |
Why?
|
| Gene Expression | 2 | 2004 | 3570 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 1493 | 0.040 |
Why?
|
| Paraffin Embedding | 2 | 2004 | 226 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 1225 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2002 | 876 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2005 | 1303 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 527 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 456 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8873 | 0.040 |
Why?
|
| Male | 7 | 2021 | 123000 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 410 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 546 | 0.040 |
Why?
|
| Sarcoma | 2 | 2003 | 1725 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1997 | 37 | 0.040 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2005 | 153 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 960 | 0.040 |
Why?
|
| Sterilization | 1 | 1996 | 13 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1756 | 0.040 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2016 | 4 | 0.040 |
Why?
|
| United States Environmental Protection Agency | 1 | 2016 | 12 | 0.040 |
Why?
|
| Disinfectants | 1 | 1996 | 35 | 0.040 |
Why?
|
| Risk | 4 | 2005 | 1972 | 0.040 |
Why?
|
| Rifampin | 1 | 1997 | 191 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1994 | 55 | 0.030 |
Why?
|
| Chlorhexidine | 1 | 1996 | 88 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1997 | 149 | 0.030 |
Why?
|
| Minocycline | 1 | 1997 | 182 | 0.030 |
Why?
|
| Forecasting | 2 | 2016 | 694 | 0.030 |
Why?
|
| Vulvitis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 160 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2002 | 4892 | 0.030 |
Why?
|
| Floxuridine | 1 | 1995 | 38 | 0.030 |
Why?
|
| Hypertension | 1 | 2005 | 1503 | 0.030 |
Why?
|
| Cell Division | 1 | 2000 | 2489 | 0.030 |
Why?
|
| Silver Staining | 1 | 1995 | 14 | 0.030 |
Why?
|
| Nucleolus Organizer Region | 1 | 1995 | 17 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1996 | 204 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 2238 | 0.030 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1994 | 19 | 0.030 |
Why?
|
| Soft Tissue Injuries | 1 | 1995 | 51 | 0.030 |
Why?
|
| Dissection | 1 | 1995 | 156 | 0.030 |
Why?
|
| Pilot Projects | 3 | 1996 | 2803 | 0.030 |
Why?
|
| Ovary | 1 | 1999 | 668 | 0.030 |
Why?
|
| Catheters, Indwelling | 3 | 1997 | 374 | 0.030 |
Why?
|
| Vagina | 1 | 1996 | 317 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1995 | 178 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 1997 | 354 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 15179 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1148 | 0.030 |
Why?
|
| Catheterization | 1 | 1996 | 410 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 502 | 0.030 |
Why?
|
| Dacarbazine | 1 | 1996 | 485 | 0.030 |
Why?
|
| Cystitis | 1 | 1994 | 107 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2005 | 2594 | 0.030 |
Why?
|
| Necrosis | 1 | 1995 | 580 | 0.030 |
Why?
|
| Chemoprevention | 1 | 1995 | 241 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2002 | 4320 | 0.030 |
Why?
|
| Proportional Hazards Models | 6 | 2004 | 4988 | 0.030 |
Why?
|
| Laparotomy | 1 | 1994 | 211 | 0.030 |
Why?
|
| Bleomycin | 3 | 2005 | 467 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 487 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2005 | 702 | 0.030 |
Why?
|
| Biomarkers, Tumor | 3 | 2004 | 10331 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2007 | 3552 | 0.030 |
Why?
|
| Time Factors | 5 | 2005 | 12926 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 1997 | 884 | 0.030 |
Why?
|
| Aorta | 1 | 1996 | 692 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 1993 | 264 | 0.030 |
Why?
|
| Receptors, Estrogen | 2 | 2003 | 2086 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 1616 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2000 | 3719 | 0.030 |
Why?
|
| Reoperation | 2 | 1994 | 1382 | 0.030 |
Why?
|
| Cross Infection | 1 | 1996 | 544 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2001 | 4938 | 0.030 |
Why?
|
| Sepsis | 1 | 1997 | 652 | 0.030 |
Why?
|
| Decision Trees | 1 | 1992 | 178 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 1544 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 6009 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 1991 | 68 | 0.020 |
Why?
|
| Melphalan | 3 | 2001 | 834 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 1996 | 1945 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1992 | 369 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 1991 | 119 | 0.020 |
Why?
|
| Splenectomy | 1 | 1991 | 158 | 0.020 |
Why?
|
| Imatinib Mesylate | 2 | 2005 | 1665 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 1991 | 178 | 0.020 |
Why?
|
| Parity | 2 | 2005 | 139 | 0.020 |
Why?
|
| Diet | 1 | 2018 | 1440 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2002 | 8223 | 0.020 |
Why?
|
| Critical Care | 1 | 1996 | 770 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 5047 | 0.020 |
Why?
|
| Stents | 1 | 1996 | 1096 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1994 | 712 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 11965 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1992 | 408 | 0.020 |
Why?
|
| Groin | 2 | 2003 | 74 | 0.020 |
Why?
|
| Erythema Multiforme | 1 | 1989 | 14 | 0.020 |
Why?
|
| Myometrium | 1 | 1989 | 79 | 0.020 |
Why?
|
| Benchmarking | 1 | 2011 | 273 | 0.020 |
Why?
|
| Benzamides | 2 | 2005 | 1832 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Mesonephroma | 1 | 1989 | 17 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 452 | 0.020 |
Why?
|
| Oncogenes | 1 | 1992 | 673 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1995 | 159 | 0.020 |
Why?
|
| Clitoris | 1 | 1988 | 7 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1992 | 584 | 0.020 |
Why?
|
| Lumbosacral Plexus | 1 | 1988 | 12 | 0.020 |
Why?
|
| Neurofibroma | 1 | 1988 | 31 | 0.020 |
Why?
|
| Bupivacaine | 1 | 1989 | 68 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1995 | 962 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 120 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 415 | 0.020 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1987 | 6 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 1987 | 14 | 0.020 |
Why?
|
| Kidney Calices | 1 | 1987 | 7 | 0.020 |
Why?
|
| Endometriosis | 1 | 1990 | 214 | 0.020 |
Why?
|
| Infant | 2 | 2002 | 13310 | 0.020 |
Why?
|
| Epinephrine | 1 | 1989 | 255 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2437 | 0.020 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1988 | 72 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 1509 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 945 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2004 | 1914 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1994 | 1529 | 0.020 |
Why?
|
| Neurilemmoma | 1 | 1988 | 127 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Androstadienes | 1 | 2008 | 165 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 289 | 0.020 |
Why?
|
| Urine | 1 | 1987 | 143 | 0.020 |
Why?
|
| Uterine Cervical Diseases | 1 | 1987 | 25 | 0.020 |
Why?
|
| Intraoperative Care | 2 | 2001 | 259 | 0.020 |
Why?
|
| Kidney Pelvis | 1 | 1987 | 102 | 0.020 |
Why?
|
| Technetium Compounds | 1 | 2006 | 12 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2004 | 4298 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1989 | 621 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 2008 | 136 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 748 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 289 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1995 | 418 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 674 | 0.020 |
Why?
|
| Ileum | 1 | 1987 | 165 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 286 | 0.020 |
Why?
|
| Radiotherapy Dosage | 3 | 2004 | 3842 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1992 | 344 | 0.020 |
Why?
|
| Methotrexate | 1 | 1989 | 999 | 0.020 |
Why?
|
| Estrogens | 1 | 1990 | 751 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 761 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 1987 | 231 | 0.020 |
Why?
|
| Teratoma | 1 | 1987 | 236 | 0.020 |
Why?
|
| Tumor Virus Infections | 1 | 1987 | 224 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 22 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 483 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2005 | 5178 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 660 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2005 | 64 | 0.020 |
Why?
|
| Palliative Care | 1 | 1996 | 2037 | 0.020 |
Why?
|
| Colectomy | 1 | 1987 | 288 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2005 | 67 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2004 | 2307 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 2992 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2005 | 129 | 0.020 |
Why?
|
| Mexico | 1 | 2005 | 259 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2004 | 79 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 104 | 0.020 |
Why?
|
| Intraoperative Period | 2 | 1995 | 246 | 0.020 |
Why?
|
| Remission Induction | 3 | 1998 | 3569 | 0.020 |
Why?
|
| Aging | 1 | 1993 | 1582 | 0.020 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 75 | 0.020 |
Why?
|
| Disease Progression | 2 | 2005 | 6682 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1988 | 1363 | 0.010 |
Why?
|
| Renal Replacement Therapy | 1 | 2005 | 135 | 0.010 |
Why?
|
| Calbindin 2 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 63 | 0.010 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2003 | 50 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 153 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 600 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 236 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2008 | 14551 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 479 | 0.010 |
Why?
|
| Keratins | 1 | 2003 | 330 | 0.010 |
Why?
|
| Retroperitoneal Space | 2 | 1995 | 145 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1987 | 691 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 498 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 1546 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 1678 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3033 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 652 | 0.010 |
Why?
|
| Cervix Uteri | 2 | 1993 | 253 | 0.010 |
Why?
|
| Topotecan | 1 | 2001 | 239 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 1489 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5539 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 191 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 608 | 0.010 |
Why?
|
| Referral and Consultation | 2 | 1999 | 899 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2000 | 72 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 121 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 667 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 448 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 367 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1996 | 2315 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2316 | 0.010 |
Why?
|
| Gold Radioisotopes | 1 | 1998 | 6 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2232 | 0.010 |
Why?
|
| Neoplasm Metastasis | 3 | 1997 | 5112 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1991 | 4367 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1999 | 105 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 528 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2005 | 2218 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 1620 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1997 | 128 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2004 | 9244 | 0.010 |
Why?
|
| HIV Infections | 1 | 1990 | 2134 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 2203 | 0.010 |
Why?
|
| Melanoma | 1 | 1994 | 5317 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2000 | 1008 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 1997 | 74 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3441 | 0.010 |
Why?
|
| Inguinal Canal | 1 | 1996 | 60 | 0.010 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 1996 | 19 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 4804 | 0.010 |
Why?
|
| Obstetrics | 1 | 1999 | 221 | 0.010 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1995 | 22 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 4971 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1996 | 242 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 1090 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 558 | 0.010 |
Why?
|
| Vincristine | 2 | 1989 | 1511 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1995 | 171 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 694 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1994 | 58 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1362 | 0.010 |
Why?
|
| Fallopian Tubes | 1 | 1995 | 119 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 2944 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 2927 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2000 | 1694 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1997 | 597 | 0.010 |
Why?
|
| Para-Aortic Bodies | 1 | 1993 | 8 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2000 | 1459 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2000 | 2084 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2003 | 2518 | 0.010 |
Why?
|
| Contraindications | 1 | 1993 | 150 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1995 | 726 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1992 | 123 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4757 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 5395 | 0.010 |
Why?
|
| Obesity | 1 | 2005 | 2884 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1996 | 764 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 1165 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1991 | 197 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 629 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1997 | 915 | 0.010 |
Why?
|
| Vulvar Diseases | 1 | 1991 | 17 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1995 | 1944 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 59536 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 1656 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 183 | 0.010 |
Why?
|
| Patient Selection | 1 | 1998 | 2055 | 0.010 |
Why?
|
| Bacteremia | 1 | 1996 | 689 | 0.010 |
Why?
|
| Morbidity | 1 | 1991 | 397 | 0.010 |
Why?
|
| Interferons | 1 | 1991 | 291 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1991 | 875 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1993 | 1391 | 0.010 |
Why?
|
| Diploidy | 1 | 1989 | 114 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 1259 | 0.010 |
Why?
|
| Spleen | 1 | 1991 | 676 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1991 | 301 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1995 | 1299 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1989 | 138 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1989 | 145 | 0.010 |
Why?
|
| Pregnancy | 2 | 1994 | 7573 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1987 | 70 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1988 | 275 | 0.000 |
Why?
|
| Puerperal Disorders | 1 | 1987 | 41 | 0.000 |
Why?
|
| Hematoma | 1 | 1988 | 160 | 0.000 |
Why?
|
| Abdomen | 1 | 1988 | 332 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1987 | 143 | 0.000 |
Why?
|
| Texas | 1 | 1997 | 6311 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4557 | 0.000 |
Why?
|
| Surveys and Questionnaires | 1 | 1996 | 5687 | 0.000 |
Why?
|
| Papillomaviridae | 1 | 1987 | 624 | 0.000 |
Why?
|
| Age Factors | 1 | 1992 | 5377 | 0.000 |
Why?
|
| Pregnancy Complications | 1 | 1987 | 526 | 0.000 |
Why?
|
| DNA | 1 | 1989 | 2693 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 7551 | 0.000 |
Why?
|